Facebook Facebook Share
Posted by Target Ovarian Cancer on Tuesday 10 October 2017

Annwen Jones reports on new members who recently have joined our Scientific Advisory Board, ahead of our forthcoming announcement about an exciting new project that we will be funding.

How do we decide what research to fund?

We place the utmost importance on funding research of the highest quality – research projects that are novel, led by outstanding scientists or clinicians and with the greatest likelihood of improving or finding new treatments for ovarian cancer. To help us decide what research to fund we have established a panel of highly expert scientists and clinicians on our Scientific Advisory Board (SAB). The role of the members of the SAB are to scrutinise in detail each research application that we receive and recommend to the Board of Trustees which ones should be funded. Funding research isn’t cheap and therefore we need to assess thoroughly where the generous donations of our supporters can best be spent.

Who helps us to decide?

Earlier this year, we were delighted that Professor Ruth Plummer agreed to become the new Chair of the SAB. Ruth is Professor of Experimental Cancer Medicine at Newcastle University, an honorary consultant medical oncologist in Newcastle Hospitals Foundation Trust and a world leader in the development of new cancer drugs. More recently, we were excited to welcome a further two new members to the SAB.

Dr Ros Glasspool is a consultant medical oncologist and NHS Research Scotland senior fellow at the Beatson West of Scotland Cancer Centre in Glasgow and honorary clinical senior lecturer at Glasgow University. Amongst many other responsibilities, Ros chairs the NCRI ovarian cancer clinical studies sub-group, which oversees the UK’s portfolio of clinical trials in ovarian cancer. Ros combines clinical work with clinical research, investigating novel therapies in ovarian cancer with a specific interest rare sub-types. Ros spoke to the All Party Parliamentary Group on ovarian cancer at Westminster and supported us with the release of Patherfinder Scotland.

Dr Rebecca Kristeleit is a Consultant Medical Oncologist and Senior Lecturer in Experimental Therapeutics at University College London. Rebecca specialises in the treatment of gynaecological cancers and research into new treatments for solid tumours. Previously, Rebecca worked at the Drug Development Unit of the Royal Marsden NHS Foundation Trust. Rebecca joined our expert panel at Being Together Hertfordshire last year.

All members have joined our Scientific Advisory Board in a voluntary capacity. From discussions at our recent meeting it is clear that they all share a significant passion and enthusiasm for scientific research and how it can solve the problems standing in the way of developing new treatments. We are fortunate to have such an esteemed group of experts working with Target Ovarian Cancer and their involvement is testament to the important work that we are able to fund through the generosity of our supporters.

Find our more